Outcomes and Clinicolopathological Features of Breast Cancer in HBOC
Main Article Content
Abstract
Background: Breast cancer is one of the leading causse of mortality and morbidity in women.Recent studies have unearthed an interesting correlation between these two types of cancers particularly with regards to genetic alterations. Hereditary breast and ovarian cancer syndrome (HBOC) is caused by pathogenic variants in BRCA and other cancer related genes.
Objectives: To evaluate the outcomes and clinicopathological features of breast cancer in HBOC.
Methodology: This Retrospective Cohort study was performed in the Department of Medical Oncology at SKMCH&RC, Lahore, Pakistan from January 1st 2020 to 31st December 2020. Forty-Two patients diagnosed with HBOC were included from the hospital medical records after analyzing hospital records for the last 25 years.Twenty-FivePatient’s out of these were 1st primary breast cancer. All information was recorded using proforma and analysed on IBM SPSS for MacBook, Version 26.0.
Results:Upon diagnosis of ovarian cancer, the most common tumor types (tumor histopathology) was found to be: Invasive Ductal Carcinoma (in 25 patients with 1st primary breast cancer in those with HBOC). Whereas diagnosis of breast cancer followed by ovarian cancer, the most common tumor types (tumor histopathology) were found to be: Invasive Ductal Carcinoma (in 15 patients with 2nd primary breast cancer in those with HBOC). This was followed by Invasive Lobular Carcinoma (2 patients with 2nd primary breast cancer in those with HBOC). 10 out of the 17 were Premenopausal and the rest 15 were postmenopausal.
Conclusion:Treating HBOC is a physician’s dilemma. Although further functional analyses are necessary to better characterize the contribution of those variants to the genetic mutations, these findings would improve the risk estimation and clinical follow-up of patients with HBOC clinical suspicion. Timely diagnosis and histopathology of the tumour type is of utmost importance in any cancer particularly in treatment of Breast cancer.